Search results
Results From The WOW.Com Content Network
Waldenström macroglobulinemia is characterized by an uncontrolled clonal proliferation of terminally differentiated B lymphocytes. The most commonly associated mutations, based on whole-genome sequencing of 30 patients, are a somatic mutation in MYD88 (90% of patients) and a somatic mutation in CXCR4 (27% of patients). [ 11]
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
The International Classification of Childhood Cancer (ICCC) is a standardized method for categorizing childhood malignancies set forth by the World Health Organization (WHO). This system bases malignancy classification on the histological traits of the tumor (type of tissue). This is opposed to the classification of adult malignancies, which ...
The myeloid cell line normally produces granulocytes, erythrocytes, thrombocytes, macrophages and mast cells; the lymphoid cell line produces B, T, NK and plasma cells. Lymphomas, lymphocytic leukemias, and myeloma are from the lymphoid line, while acute and chronic myelogenous leukemia, myelodysplastic syndromes and myeloproliferative diseases ...
Combined small cell lung carcinoma (or c-SCLC) is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of;small cell lung carcinoma (SCLC), admixed with one (or more) components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion.
Oncology. Non-small-cell lung cancer ( NSCLC ), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. [ 1][ 2][ 3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma.
Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer. [5] [6] [7]The most common side effects include leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation ...
NCI/ADR-RES appears to have been derived at some point in time from cell line OVCAR-8. Originally the cell line was named MCF-7/ADR-RES; it was renamed together with the change in classification. Two brain cancer cell lines, SNB-19 and U251, were discovered to come from the same person. This makes a mixup likely.